There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Ultragenyx Pharmaceutical (RARE – Research ...

Look no further than our top two stories of the year, and you’ll see that the GLP-1 craze and Big Pharma layoffs took center ...

Madrigal Pharmaceuticals, X4 Pharmaceuticals and Day One Biopharmaceuticals secured their maiden approvals this year in metabolic dysfunction-associated steatohepatitis, WHIM syndrome and pediatric ...

Detailed price information for Novo Nordisk A/S ADR (NVO-N) from The Globe and Mail including charting and trades.

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Arcturus Therapeutics (ARCT – Research Report) ...

Altimmune is redefining success in both obesity and MASH to position Pemvidutide in blue ocean categories. Read why I rate ...

Shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Get Free Report) have been assigned a consensus recommendation of “Moderate Buy” from the thirteen ratings firms that are presently covering the ...

Explore Baker Brothers' biotech-focused 13F portfolio, with notable stake increases in Incyte, Summit Therapeutics, and other ...

Genesis Therapeutics, a company pioneering artificial intelligence (AI) technologies to create breakthrough medicines for patients, today announced the appointments of three key members during 2024 to ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Since then, Madrigal has been focused on getting more patients on treatment so that it can generate sales. In the third quarter, there were more than 6,800 patients taking Rezdiffra, which led to ...

Madrigal Pharmaceuticals, Inc. has a 1 year low of $168.25 and a 1 year high of $368.29. The business has a 50-day moving average of $272.33 and a 200-day moving average of $262.18.